Immune and stromal remodeling underlies radiation-induced heart injury: insights from single-cell transcriptomics - Summary - MDSpire

Immune and stromal remodeling underlies radiation-induced heart injury: insights from single-cell transcriptomics

  • By

  • Xia Yan

  • JiaYi Zhao

  • QinYing Shi

  • Rui Yan

  • Sijin Li

  • Jianbo Song

  • July 2, 2026

  • 0 min

Share

Objective:

To investigate the cellular and molecular mechanisms driving radiation-induced heart injury (RIHI) using single-cell RNA sequencing.

Approach:
  • Single-cell RNA sequencing: Performed on rat hearts and matched peripheral blood mononuclear cells (PBMCs) 12 weeks post whole-heart irradiation (20 Gy) or sham control, profiling 38,941 cardiac cells and 41,097 PBMCs.
  • Analytical methods: Conducted differential expression, pathway enrichment, pseudotime, and ligand-receptor interaction analyses; validated key findings using Western blotting and flow cytometry.
Key Findings:
  • Defined major cardiac populations, including cardiomyocytes, endothelial cells, fibroblasts, and various immune cells in control and RIHI hearts.
  • Endothelial cells exhibited subtype shifts and marked MHC-II upregulation post-irradiation.
  • Fibroblasts showed iron accumulation and pro-inflammatory activation with antigen-presenting properties.
  • Myeloid activation and T/NK cell polarization toward cytotoxic but partially exhausted states were observed.
  • Enhanced B-cell antigen presentation was noted, linking radiation injury to chronic cardiac inflammation.
Interpretation:

RIHI progresses through a stromal-immune cascade where endothelial and fibroblast immunogenic reprogramming initiates sustained myeloid and lymphoid activation, creating a pro-inflammatory cardiac microenvironment.

Limitations:
  • Study conducted in a rat model, which may not fully replicate human responses to radiation.
  • Focus on specific time points post-irradiation may overlook earlier cellular changes.
Conclusion:

Findings suggest non-hematopoietic antigen presentation as a potential therapeutic target in thoracic radiotherapy, especially in combination with immune checkpoint inhibitors.

Original Source(s)

Related Content